ArticleInternational journal of molecular sciences2026
A Pan-Cancer Analysis of microRNA Tissue Specificity and Its Association with Dysregulation.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
MicroRNAs are frequently dysregulated in cancer, yet how their tissue specificity is remodeled during malignant transformation remains poorly characterized. Here, we systematically quantified the tissue specificity of miRNAs across normal (GTEx) and cancer (TCGA) tissues using the Tau index as the primary metric and the Gini index for independent validation. Our analysis revealed a negative association between tissue specificity in healthy tissues and changes in specificity during malignant transformation, indicating that miRNAs with higher tissue specificity in normal tissues tend to undergo greater loss of specificity in cancer. To robustly define dysregulation, we combined two independent analyses: a binomial test over per-project differential expression across 17 matched normal tissues within the TCGA cohort, and a TCGA-GTEx pan-tissue comparison of mean expression. The change in specificity (ΔTau) separated up- from downregulated miRNAs, showing moderate agreement with the binomial signal and a strong correlation with the expression-based contrast. Finally, we identified six miRNAs that lose tissue specificity upon transformation while remaining consistently upregulated (miR-519a-5p, miR-512-3p, miR-522-3p, miR-105-5p, miR-935, miR-1269a). Functional analysis of their experimentally validated and predicted targets showed significant enrichment for converging on core oncogenic programs. Collectively, integrating specificity dynamics with dysregulation evidence pinpoints candidate miRNAs with coordinated, cancer-relevant regulatory roles and highlights those with favorable tissue-specificity profiles that may warrant further investigation as potential therapeutic candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.